Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi
Authors:
- F. MicoliFMF. Micoli
- S. RondiniSRS. Rondini
- I. PisoniIPI. Pisoni
- C. GiannelliCGC. Giannelli
- V. Di CioccioVCV. Di Cioccio
- P. CostantinoPCP. Costantino
- A. SaulASA. Saul
- L.B. MartinLML.B. Martin
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Safety, Immunogenicity and Dose Ranging of a New Vi-CRM197 Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy AdultsPLOS ONE, 2011
- The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant VaccinesClinical and Vaccine Immunology, 2011
- Evaluation of the Immunogenicity and Biological Activity of the Citrobacter freundii Vi-CRM 197 Conjugate as a Vaccine for Salmonella enterica Serovar TyphiClinical and Vaccine Immunology, 2011
- Global Trends in Typhoid and Paratyphoid FeverClinical Infectious Diseases, 2010
- Physical and Chemical Characterization and Immunologic Properties ofSalmonella entericaSerovar Typhi Capsular Polysaccharide-Diphtheria Toxoid ConjugatesClinical and Vaccine Immunology, 2010
- Bacteremic Typhoid Fever in Children in an Urban Slum, BangladeshEmerging Infectious Diseases, 2005
- Effect of Dosage on Immunogenicity of a Vi Conjugate Vaccine Injected Twice into 2- to 5-Year-Old Vietnamese ChildrenInfection and Immunity, 2004
- The Efficacy of aSalmonella typhiVi Conjugate Vaccine in Two-to-Five-Year-Old ChildrenNew England Journal of Medicine, 2001
- Use and Validation of an NMR Test for the Identity and O -acetyl content of the Salmonella typhi Vi Capsular Polysaccharide VaccineBiologicals, 2000
- PROTECTIVE ACTIVITY OF VI CAPSULAR POLYSACCHARIDE VACCINE AGAINST TYPHOID FEVERThe Lancet, 1987